AIM ImmunoTech Announces Release of the Next CEO Corner Segment https://bit.ly/3yizvQA #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
AIM ImmunoTech
Pharmaceutical Manufacturing
Ocala, FL 1,251 followers
Biotech company researching and developing therapeutics to treat various cancers and immune-deficiency disorders.
About us
AIM ImmunoTech Inc., an immuno-pharma company headquartered in Ocala, Florida, is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older. We operate a 30,000-square-foot facility in New Brunswick, NJ to produce Ampligen® and Alferon®. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.
- Website
-
http://www.aimimmuno.com
External link for AIM ImmunoTech
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Ocala, FL
- Type
- Public Company
Locations
-
Primary
2117 SW Highway 484
Ocala, FL 34473, US
Employees at AIM ImmunoTech
-
Ellen Lintal
CFO | VP Finance | VP Controller | Manufacturing | Non Profit| Sarbanes Oxley
-
Stewart Appelrouth
Citrin Cooperman and Member of the Board of Directors at AIM ImmunoTech, Inc.
-
Ann Marie E. Coverly
Director of Human Resources and Administration; Deputy Investor Relations Coordinator
-
Dean Maude
Jr Accountant at AIM ImmunoTech Inc.
Updates
-
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy https://bit.ly/4fdZPvV #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy | AIM Immunotech
https://aimimmuno.com
-
Catch up on our previously released #CEOCorner segments and keep an eye out for more! Have a topic for Tom? Enter your suggestion here: https://bit.ly/3TcXCGM #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
-
-
Listen to our CEO, Tom Equels, give a “Quick Pitch” on the AIM opportunity at the recent Virtual Investor Pitch Conference. Access the full webcast replay here: https://bit.ly/3Xguylq #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
-
Take a look at our latest corporate presentation here: https://bit.ly/3LzqZ3D #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
Presentations | AIM Immunotech
https://aimimmuno.com
-
Our CEO, Tom Equels, describes the AIM opportunity at the recent Virtual Investor Pitch Conference. Access the full webcast replay here: https://bit.ly/3Xguylq #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
-
Never miss an update by signing up for our email alerts. https://bit.ly/3Cwfrse #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
-
-
#InCaseYouMissedIt: We recently participated in the Virtual Investor Pitch Conference! Access the webcast replay here: https://bit.ly/3Xguylq #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
Welcome! You are invited to join a webinar: Virtual Investor Pitch: AIM ImmunoTech (NYSE American: AIM) . After registering, you will receiv...
us02web.zoom.us
-
Wishing everyone a happy Independence Day! #4thofJuly2024
-
-
AIM ImmunoTech Announces Release of the Next CEO Corner Segment https://bit.ly/4cPHAuN #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS
AIM ImmunoTech Announces Release of the Next CEO Corner Segment | AIM Immunotech
https://aimimmuno.com